1. Home
  2. MYO vs CNTX Comparison

MYO vs CNTX Comparison

Compare MYO & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myomo Inc.

MYO

Myomo Inc.

HOLD

Current Price

$1.11

Market Cap

44.8M

Sector

Health Care

ML Signal

HOLD

Logo Context Therapeutics Inc.

CNTX

Context Therapeutics Inc.

HOLD

Current Price

$0.63

Market Cap

51.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYO
CNTX
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.8M
51.5M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
MYO
CNTX
Price
$1.11
$0.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$7.67
$6.60
AVG Volume (30 Days)
956.4K
5.3M
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.39
EPS
N/A
N/A
Revenue
$1,000,000,000.00
N/A
Revenue This Year
$9.10
N/A
Revenue Next Year
$13.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40814.79
N/A
52 Week Low
$0.61
$0.55
52 Week High
$2.22
$3.62

Technical Indicators

Market Signals
Indicator
MYO
CNTX
Relative Strength Index (RSI) 48.91 30.60
Support Level $0.69 $0.55
Resistance Level $1.17 $0.70
Average True Range (ATR) 0.10 0.07
MACD -0.01 0.06
Stochastic Oscillator 44.64 51.05

Price Performance

Historical Comparison
MYO
CNTX

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Share on Social Networks: